Feasibility of a new electronic patient-reported outcome (ePRO) system for an advanced therapy clinical trial in immune-mediated inflammatory disease: the PROmics system (Preprint)
Authors:
- Christel McMullanCMChristel McMullan
- Sarah E HughesSHSarah E Hughes
- Anna L RoweARAnna L Rowe
- Ameeta RetzerARAmeeta Retzer
- Camilla BathurstCBCamilla Bathurst
- Rosie HardingRHRosie Harding
- Derek KyteDKDerek Kyte
- Elin Haf DaviesEDElin Haf Davies
- Roger WilsonRWRoger Wilson
- Philip N NewsomePNPhilip N Newsome
- Anita WalkerAWAnita Walker
- Olalekan Lee AiyegbusiOAOlalekan Lee Aiyegbusi
Preprint
- 7 May 2026
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
BACKGROUND Advanced therapy medicinal products (ATMPs) are increasingly evaluated in early-phase clinical trials, where understanding patient-reported symptoms, tolerability, and health-related quality of life is critical. Electronic patient-reported outcome (ePRO) systems offer potential advantages over paper-based methods, but evidence on their feasibility and acceptability in ATMP trials remains limited. OBJECTIVE To assess the feasibility and acceptability of the PROmics ePRO system when deployed within a phase II, multi-disease ATMP clinical trial involving patients with immune-mediated inflammatory diseases. METHODS A qualitative interview-based feasibility study was embedded within the POLARISE trial, a multicentre phase II ATMP basket trial investigating ORBCEL-C™ in patients with rheumatoid arthritis, primary sclerosing cholangitis, Crohn’s disease, and lupus nephritis. Semi-structured interviews were conducted with trial participants and research and clinical staff who used the PROmics system. Interviews explored experiences of training, usability, questionnaire burden, real-time alerts, and integration within trial workflows. Transcripts were thematically analysed using the framework method. RESULTS Fourteen participants were interviewed (seven patients and seven staff). Overall, the PROmics system was perceived as acceptable, intuitive, and easy to use by both patients and staff. Automated reminders and real-time alerts were key facilitators of engagement and provided reassurance to patients that their symptoms were actively monitored. However, several feasibility challenges were identified, including technical issues, uncertainty around support pathways, questionnaire burden, and the workload associated with managing alerts. Staff turnover and limitations in clinical dashboard usability and system integration further increased implementation burden. CONCLUSIONS The PROmics ePRO system was acceptable and valued by patients and staff in the context of an ATMP trial, but successful implementation requires careful attention to technical stability, user support, questionnaire scheduling, and alert management within existing trial infrastructure. Addressing these issues is essential to maximise the feasibility, sustainability, and value of digital PROM collection in future ATMP clinical trials. CLINICALTRIAL n/a INTERNATIONAL REGISTERED REPORT RR2-10.1136/bmjopen-2022-063199Keywords
This publication has 47 references indexed in Scilit:
- Methods for implementing and reporting the Patient‐Reported Outcomes version of the Common Terminology Criteria for Adverse Events to measure patient‐reported adverse events in cancer clinical trialsCancer, 2025
- Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic CancerJAMA, 2022
- Novel cell-based therapies in inflammatory bowel diseases: the established concept, promising resultsHuman Cell, 2021
- Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial ProtocolsJAMA, 2018
- Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrumentHepatology, 2017
- Validity and usefulness of a single‐item measure of patient‐reported bother from side effects of cancer therapyCancer, 2017
- Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)JAMA Oncology, 2015
- News from the NIH: Person-centered outcomes measurement: NIH-supported measurement systems to evaluate self-assessed health, functional performance, and symptomatic toxicityTranslational Behavioral Medicine, 2015
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- The Fatigue Severity ScaleArchives of Neurology, 1989